Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $209.10 | Total: $1,045.50 |
| 1 | 10 | $177.12 | Total: $1,771.20 |
| 1 | 25 | $150.06 | Total: $3,751.50 |
| 1 | 50 | $127.92 | Total: $6,396.00 |
| 1 | 100 | $110.70 | Total: $11,070.00 |
Overview
Lys-SMCC-DM1 (Lys-N?-MCC-DM1) is an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2). It contains the microtubule polymerization inhibitor DM1 as the active metabolite, which inhibits microtubule polymerization. It is commonly used in breast cancer research.
Chemical Properties
| Molecular Formula | C53H75ClN6O15S |
| Molecular Weight | 1103.71 |
| CAS Numbers | 1281816-04-3 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C[C@]12[C@@](O1)([C@H](C)[C@@]3(C[C@](O)([C@H](OC)C=CC=C(C)CC4=CC(N(C)C(=O)C[C@@H]2OC([C@@H](N(C(CCS[C@@H]5C(=O)N(C[C@@H]6CC[C@@H](C(NCCCC[C@@H](C(O)=O)N)=O)CC6)C(=O)C5)=O)C)C)=O)=C(Cl)C(OC)=C4)NC(=O)O3)[H])[H] |
Storage and Handling
0C Short Term, -20C Long Term
References
Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107[7] 1039-46.